ASX Announcement
30th July 2026

RHYTHM BIOSCIENCES

For personal use only

Appendix 4C for the Quarter Ended 30 June 2026

Q4 FY26 Highlights

- ✓ **Strengthened Company Balance Sheet** – via the underwriting of ~$5.2m of RHYO $0.20 options (less costs), supporting continued commercial execution activities.
- ✓ **Commercial rollout of ColoSTAT®** - momentum continues to build with repeat clinical ordering, following the Company's first commercial sale in Q3 FY26.
- ✓ **National collection capability expanded** - through the further addition of 4Cyte Pathology collection centres, strengthening Australia's commercial testing infrastructure.
- ✓ **ColoSTAT® Access Program expanded to sixteen nationally recognised clinicians** - increasing real-world evidence generation while broadening the Company's key opinion leader (KOL) network.
- ✓ **Extensive Voice of Customer research completed** - which translated into a national GP marketing campaign through AusDoc, targeting more than 20,000 Australian general practitioners.
- ✓ **Early commercial adoption demonstrated ColoSTAT® successfully reaching elderly, regional and mobility-limited patients** - through home and community blood collection.
- ✓ **Strong international commercial engagement** - generated at BIO International Convention 2026, creating multiple strategic partnering opportunities across key global markets.

Rhythm Biosciences Managing Director and CEO, Dr David Atkins commented:
"Q4 FY26 marked another important milestone in Rhythm's evolution into a commercial precision diagnostics company. Following our first commercial ColoSTAT® sale in the previous quarter, our focus shifted to demonstrating repeat clinical adoption while strengthening the commercial capabilities required to support sustainable growth.

During the quarter, we expanded our national collection network through 4Cyte Pathology, grew participation in the ColoSTAT® Access Program, completed comprehensive Voice of Customer research that is now informing our national GP engagement strategy and increased awareness of ColoSTAT® through targeted education and marketing initiatives.

Most encouragingly, we continued to see evidence of ColoSTAT® being incorporated into routine clinical practice. Patients from a broad range of settings—including elderly, regional and mobility-limited individuals—were able to access testing through home and community-based blood collection services. These early clinical experiences demonstrate both the accessibility of our testing model and the potential for ColoSTAT® to become an increasingly integrated part of patient management.

Beyond Australia, our participation at BIO International Convention 2026 generated valuable engagement with several global diagnostics and healthcare organisations. These discussions have broadened our strategic partnership pipeline and reinforce our confidence in the international potential of both ColoSTAT® and geneType™.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Gavin Fox-Smith	Non-Executive Chair
Sue MacLeman	Non-Executive Director
David Atkins	CEO & Managing Director

As we enter FY27, our priorities remain clear: continue increasing commercial adoption, deepen clinician engagement, advance independent validation and reimbursement initiatives and convert our growing pipeline of strategic opportunities into long-term commercial value. Hence, we believe Rhythm is well positioned to build on the commercial progress achieved to date through disciplined execution of our growth strategy."

Melbourne, Australia, 30th July 2026: Rhythm Biosciences Ltd (ASX: **RHY**) ("**Rhythm**" or the "**Company**"), a commercial-stage precision diagnostics company advancing earlier cancer detection and personalised risk assessment with complementary platforms in cancer risk assessment and disease detection, today releases its Quarterly Activities Report and Appendix 4C for the quarter ended 30 June 2026 (**Q4 FY26**).

Review of Q4 FY26 Stated Milestones

During Q4 FY26, the Company delivered meaningful progress across each of the key milestones established at the conclusion of the previous quarter, thereby strengthening the commercial foundations of both the ColoSTAT® and geneType™ platforms.

- ✓ **Increase ColoSTAT® test volumes through the 4Cyte network and ColoSTAT® Access Program** — Commercial adoption and market activity for ColoSTAT® accelerated through further growth of the 4Cyte Pathology collection network and the ongoing expansion of the ColoSTAT® Access Program. These initiatives were supported by targeted clinician education, participation in primary care conferences, customer webinars and the launch of a national GP awareness campaign, broadening market engagement and supporting increasing clinical utilisation.
- ✓ **Progress the ColoSTAT® analytical evaluation at the Southern Hub laboratory (Royal Surrey NHS Foundation Trust) toward completion** —the independent analytical evaluation, which commenced in February 2026, continued to progress during the quarter. This evaluation remains an important component of the Company's international validation strategy and supports future commercial, reimbursement and market access opportunities.
- ✓ **Expansion of geneType™ domestic and international commercial partnerships** — Commercial momentum across the geneType™ platform continued to build during the quarter. Previously announced partners, including KYL and CancerIQ in the United States, generated increasing patient testing activity, while discussions with additional domestic and international commercial partners progressed, expanding opportunities for future market development.
- ✓ **Advance strategic pathways for ColoSTAT® commercial expansion** — Rhythm further strengthened its commercial relationship with 4Cyte Pathology while advancing discussions with several additional strategic partners in Australia and internationally. Engagement with prospective partners at BIO International Convention 2026 further expanded the Company's commercial opportunity pipeline, with several discussions progressing to follow-up engagement.

The Company believes the progress achieved during Q4 FY26 has strengthened its commercial position and provides a solid platform to support continued execution of its growth strategy throughout FY27.

Commercial Diagnostic Portfolio

Rhythm has established two complementary commercial diagnostic platforms that address different stages of the patient journey - from identifying individuals at elevated disease risk through to assisting clinicians with earlier disease detection.

Together, **ColoSTAT®** and **geneType™** position the Company across the continuum of precision medicine, providing multiple commercial opportunities within large and growing healthcare markets while creating diversified pathways for future revenue generation.

ColoSTAT® – Blood-Based Colorectal Cancer Detection

Originally emanating from research conducted by the CSIRO (who remain a shareholder) and later through Rhythm, ColoSTAT® is Rhythm's proprietary blood-based diagnostic test designed to assist clinicians in detecting colorectal cancer (CRC), currently specialising in symptomatic patients.

Using five proprietary protein biomarkers measured from a standard blood sample, ColoSTAT® has demonstrated **91% sensitivity across all stages of colorectal cancer (Stages I–IV)**. The test integrates into existing pathology workflows, providing clinicians with an accessible tool to support patient triage by identifying individuals who may benefit from prompt colonoscopy while reducing unnecessary procedures for lower-risk patients.

Commercial rollout continues through Rhythm's partnership with 4Cyte Pathology, with ongoing expansion of collection infrastructure and clinician engagement supporting increasing market access across Australia.

geneType™ – Precision Risk Assessment

geneType™ is Rhythm's precision medicine platform that combines polygenic risk scores with clinical, family history and lifestyle information to deliver personalised disease risk assessment.

The platform currently supports risk assessment across multiple disease areas, including breast cancer, colorectal cancer, ovarian cancer, prostate cancer, melanoma and cardiovascular disease.

Commercialisation continues through a growing network of domestic and international partners, providing Rhythm with a complementary revenue-generating platform that broadens the Company's participation across precision healthcare.

Together, ColoSTAT® and geneType™ provide Rhythm with two complementary commercial platforms addressing both disease risk assessment and disease detection.

Commercial Execution: Building a Scalable ColoSTAT® Business

Q4 FY26 represented an important phase in Rhythm's commercial evolution, with the Company's focus shifting from initial market entry to establishing the operational, clinical and commercial foundations required to support scalable growth in ColoSTAT® utilisation.

Market Insight Supporting Commercial Execution

During the quarter, Rhythm completed an extensive Voice of Customer research program involving Australian general practitioners and referring clinicians.

The research identified key drivers of clinician adoption together with practical barriers to utilisation within routine clinical practice. These insights have now been incorporated into the Company's commercial strategy and directly informed the design of a national GP awareness campaign launched through the AusDoc platform.

By aligning commercial activities with clinician feedback, Rhythm is seeking to improve the effectiveness of customer engagement while supporting broader adoption of ColoSTAT®.

National Infrastructure Expanded

A scalable diagnostics business requires accessible and reliable pathology infrastructure.

During Q4 FY26, Rhythm continued expanding its partnership with 4Cyte Pathology through activation of additional ColoSTAT® collection centres across Australia.

The growing collection network improves patient accessibility, supports referring clinicians and provides the operational capability required to accommodate increasing commercial demand as utilisation expands.

Clinician Engagement Strengthened

Increasing clinician awareness remains central to commercial adoption. During the quarter, Rhythm implemented a coordinated engagement strategy combining professional education, conference participation, digital communication and peer-to-peer advocacy.

Key initiatives included:

- Delivery of clinician education webinars and professional meetings.
- Participation at GP conferences, generating significant engagement with primary care clinicians.
- Launch of a 12-week national AusDoc campaign targeting more than 20,000 Australian general practitioners.
- Continued expansion of the ColoSTAT® Access Program, strengthening the Company's growing network of key opinion leaders and clinical advocates.

Demand generated through these activities is managed by Rhythm's commercial team in collaboration with 4Cyte Pathology's national business development network.

Early Commercial Adoption

The quarter also provided encouraging evidence of early commercial adoption, with ColoSTAT® continuing to be incorporated into routine clinical practice.

Importantly, testing expanded across diverse patient groups, including elderly, regional and mobility-limited individuals accessing home and community-based pathology services.

These real-world clinical experiences demonstrate the accessibility of the Company's testing model and support Rhythm's objective of integrating ColoSTAT® into established diagnostic pathways.

Building on the commercial foundations established during Q4 FY26, the Company intends to expand patient awareness initiatives designed to encourage appropriate discussions between patients and their healthcare professionals regarding access to ColoSTAT® testing.

Independent Evaluation Progressing

Independent analytical evaluation of ColoSTAT® continued during the quarter at the Southern Hub Laboratory in Guildford, England, part of the Royal Surrey NHS Foundation Trust and one of the five laboratories supporting the NHS England Bowel Cancer Screening Programme.

The evaluation is assessing the analytical performance of ColoSTAT® following successful technology transfer completed earlier in FY26. Progression of this independent evaluation represents an important component of Rhythm's international validation strategy and supports the generation of high-quality external evidence that may assist future commercial expansion, reimbursement initiatives and international market access opportunities.

The Company will continue to update shareholders as significant milestones are achieved.

Corporate Update

Strengthened Financial Position

During the quarter, the underwriting of the RHYO options by CPS Capital Group Pty Ltd was completed, finalising the March 2026 options exercise and strengthening the Company's working capital position. The final underwritten amount totalled $5.2m, less associated costs.

Expanding Strategic and Investor Engagement

Rhythm continued to strengthen its engagement with shareholders, investors and strategic partners throughout the quarter as commercial activity expanded.

The Company hosted an investor webinar during May 2026 and conducted an investor briefing in Singapore during June, supporting continued engagement with both Australian and international investors while increasing awareness of Rhythm's commercial strategy.

International Commercial Strategic Partners
A key strategic priority remains the expansion of commercial partnerships capable of accelerating market access and international growth.

During Q4 FY26, Rhythm participated in BIO International Convention 2026 in San Diego, one of the biotechnology sector's premier global partnering events. Management held multiple meetings with leading diagnostics companies, healthcare organisations and prospective commercial partners across several international markets.

These engagements generated several promising commercial opportunities across both ColoSTAT® and geneType™, with follow-up discussions continuing as the Company works towards establishing additional strategic partnerships.

Cost Optimisation and Cash Runway
During the quarter, the Company implemented a series of targeted operational initiatives designed to improve capital efficiency while maintaining focus on its core strategic priorities and development programs. These measures included changes to the executive leadership structure, restructuring of laboratory director arrangements, optimisation of research and development staffing, together with several additional operating cost reductions across the business.

These initiatives are expected to materially reduce the Company's ongoing monthly cash operating expenditure while preserving the capability required to execute its commercialisation and development strategy.

As a result of these actions and an expected acceleration in revenues in addition to further Research and Development Tax Incentive (RDTI) funding, based upon the Company's current operating plan, management expects existing cash reserves to provide a funding runway through to 4Q FY27, rather than that indicated in the Appendix 4C. This remains subject to the timing of operating activities and working capital requirements.

The Board believes these initiatives position the Company to advance its strategic objectives with a stronger financial foundation and enhanced capital discipline while continuing to pursue value-creating opportunities for shareholders.

Cash and Cash Equivalents as of 30 June 2026
Cash and cash equivalents on 30 June 2026 are detailed in the accompanying Appendix 4C.

During the quarter, Rhythm continued to maintain disciplined capital management while directing investment towards activities that support long-term commercial growth, including clinician engagement, market development, commercial infrastructure and strategic partnership initiatives.

The strengthened balance sheet, following completion of the RHYO option underwriting, provides an appropriate platform from which to continue executing the Company's commercial strategy.

In accordance with ASX Listing Rule 5.3.5, payments to related parties during the quarter comprised directors' fees, executive remuneration and statutory superannuation obligations only.

Q1 FY27 Commercial Priorities

Having strengthened its commercial foundations during Q4 FY26, Rhythm enters FY27 focused on expanding market access, clinician engagement and commercial infrastructure into sustained growth in diagnostic utilisation. Key operational priorities for Q1 FY27 include:

- **Continue expanding the ColoSTAT® Access Program and the national 4Cyte Pathology collection network** - to improve clinician participation and patient accessibility.
- **Further increased awareness of ColoSTAT®** - through targeted engagement with general practitioners and specialist clinicians.
- **Complete the Australian health economic analysis** - evaluating the potential clinical and economic benefits of ColoSTAT®.
- **Continue progressing the independent analytical evaluation of ColoSTAT®** - at the Southern Hub Laboratory (Royal Surrey NHS Foundation Trust).
- **Expand domestic and international commercial partnerships for geneType™** - while advancing opportunities generated through BIO International Convention 2026.
- **Commence development of a United States reimbursement strategy for geneType™** - supporting future commercial expansion within a key international market.

Execution against these priorities is intended to further strengthen Rhythm's commercial position while supporting continued growth across both diagnostic platforms.

Looking Ahead: From First Sale to Everyday Practice

Q4 FY26 marked another important stage in Rhythm's transition from product commercialisation to building a scalable precision diagnostics business.

Over the past six months, the Company has established and strengthened many of the core elements required for sustainable commercial growth. National pathology infrastructure has expanded, clinician engagement has increased, commercial marketing capabilities have matured, early real-world adoption has been demonstrated, and strategic partnership opportunities have broadened both domestically and internationally.

Importantly, these initiatives are mutually reinforcing. Expanded collection infrastructure improves patient access, clinician engagement supports test utilisation, independent validation strengthens confidence in the technology and commercial partnerships have the potential to extend market reach.

As Rhythm enters FY27, management's focus remains firmly on disciplined commercial execution. The Company will continue investing in initiatives that support increasing utilisation of ColoSTAT®, expansion of geneType™ partnerships, progression of reimbursement strategies and development of additional commercial opportunities in Australia and internationally.

Today, Rhythm is executing with two complementary commercial diagnostic platforms, expanding market access, growing clinician engagement and an increasing pipeline of strategic opportunities.

Management believes the progress achieved to date provides a stronger foundation from which to continue building a sustainable, commercial precision diagnostics business focused on delivering long-term value for patients, healthcare providers and shareholders.

Related Party Payments

In line with its obligations under ASX Listing Rule 5.3.5, Rhythm Biosciences Limited notes that the only payments to related parties of the Company, as disclosed in the Appendix 4C for the period ended 30 June 2026, pertain to payments to directors for fees, salary, and superannuation.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.
For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences
Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to collaborating with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®
Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™
geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalised health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

RHYTHM BIOSCIENCES LIMITED

ABN	**Quarter ended ("current quarter")**
59 619 459 335	30 JUNE 2026

Consolidated statement of cash flows			**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**			
1.1	Receipts from customers		18	75
1.2	Payments for			
	(a)	research and development	(713)	(3,080)
	(b)	product manufacturing and operating costs	(298)	(1,094)
	(c)	advertising and marketing		
	(d)	leased assets		
	(e)	staff costs (not included above)	(265)	(1,019)
	(f)	administration and corporate costs	(452)	(1,710)
1.3	Dividends received (see note 3)			
1.4	Interest received		41	76
1.5	Interest and other costs of finance paid		(2)	(76)
1.6	Income taxes paid			
1.7	Government grants and tax incentives			1,576
1.8	Other			
1.9	**Net cash from / (used in) operating activities**		**(1,671)**	**(5,252)**

2.	**Cash flows from investing activities**			
2.1	Payments to acquire or for:			
	(a)	entities		
	(b)	businesses		
	(c)	property, plant and equipment	(20)	(21)
	(d)	investments		
	(e)	intellectual property		

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
	(f) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		3
	(d) investments		
	(e) intellectual property		
	(f) other		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	**Net cash from / (used in) investing activities**	**(20)**	**(18)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		3,749
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options	4,157	5,277
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(332)	(524)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings	(85)	(1,275)
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	**Net cash from / (used in) financing activities**	**3,740**	**7,227**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,305	1,397
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,671)	(5,252)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(20)	(18)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	3,740	7,227
4.5	Effect of movement in exchange rates on cash held		
4.6	**Cash and cash equivalents at end of period**	**3,354**	**3,354**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	3,354	1,305
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other – short term deposit		
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**3,354**	**1,305**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	197
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Payments in 6.1 relate to Director fees and salaries.

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	85	85
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	**Total financing facilities**	85	85
7.5	**Unused financing facilities available at quarter end**		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	Clearmatch insurance funding loan. Unsecured. Interest rate: 9.06% p.a. Matures on 25/10/2026 with fixed monthly repayments.		

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,671)
8.2	Cash and cash equivalents at quarter end (item 4.6)	3,354
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	3,354
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	2.007

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: n/a

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: n/a

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: n/a

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: .....30 JULY 2026..

Authorised by: .....BY THE BOARD..
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.